Showing results (501-510 of 635) with videos related to
Sort By:
Pageof 64
Journal of the American Medical Informatics Association : JAMIA|December 13, 2024
Effectiveness of electronic medical record-based strategies for death and hospital admission endpoint capture in pragmatic clinical trialsMaryam Rahafrooz, Danne C Elbers, Jay R Gopal, et al.European Heart Journal|January 12, 2023
Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fractionJames P Curtain, Carly Adamson, Toru Kondo, et al.European Journal of Heart Failure|March 2, 2026
Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trialYasuhiro Hamatani, Brian L Claggett, Ian J Kulac, et al.Journal of the American Heart Association|December 24, 2024
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HFSimone Solano, Mingming Yang, Paolo Tolomeo, et al.Journal of the American College of Cardiology|November 3, 2024
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian L Claggett, et al.Circulation. Heart Failure|December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trialSanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.Journal of the American College of Cardiology|April 23, 2021
Incidence and Outcomes of Pneumonia in Patients With Heart FailureLi Shen, Pardeep S Jhund, Inder S Anand, et al.JACC. Heart Failure|September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.European Journal of Heart Failure|August 26, 2023
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trialMaria Pabon, Brian L Claggett, Xiaowen Wang, et al.JACC. Heart Failure|February 5, 2025
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVERMingming Yang, Toru Kondo, Atefeh Talebi, et al.Pageof 64